Kedrion Group: investments and acquisitions to expand its market share
Kedrion Group, the Italian leader in the development, manufacture and distribution of plasma derived medicinal products, continues its investment policy. Composed of nine companies based in the United States, Mexico, Switzerland, Germany, Austria and Hungary, the eighth largest group in the world, with offices in over 40 countries, Kedrion group has started a new reorganisation
Increased product range: studies on Fibrin Glue just started
Kedrion’s initiatives to strengthen and extend its market share are going on. With the start of its clinical trials on fibrin glue, the company started a plan that, if these trials prove successful, should enable it to market the new product in 2011. In order to extend its product range, the company started clinical trials
New method for the purification of Factor VIII VIII/FVW concentrate study published on
The study Progress in large-scale purification of Factor VIII/von Willebrand factor concentrates using ion-exchange chromatographyhas been published on “Vox Sanguinis” (2008) 95, 298–307, Entirely conducted by Kedrion’s researchers, the study presents the results of the development of a new purification method for a Factor VIII/von Willebrand Factor concentrate. A process scale-up is now being investigated
Viral Risk Assessment: Kedrion wins the SIMTI award
As part of the XXXVIII National Conference on Transfusion Medicine, the Scientific Committee of SIMTI (Italian Society of Transfusion and Immunohaematologic Medicine) has selected, as the winner for the session “transfusion-transmitted diseases”, the presentation Viral Risk Assessment – Modello Kedrion: applicazione nell’ambito del plasma italiano destinato alla lavorazione industriale (Viral Risk Assessment – Kedrion’s model:
Four new departments in the Bolognana site. Investiments in continuous plant and process improvement Keep Flowing
The investments for the continuous improvement of the manufacturing processes and plants of Kedrion are going on at a fast pace. After passing the AIFA inspection (AIFA is the Italian Drugs Agency) and proving to comply with international Good Manufacturing Practices (GMP), the process for the authorisation to operate with four new departments in the
Agreement between Kedrion and ProMetic for the development of Hyperimmune products
Kedrion S.p.A. and ProMetic Life Sciences Inc. (TSX:PLI) announced that they have signed the definitive agreement for two hyperimmunes. The first product to be developed will target the Hepatitis B Hyperimmune. Kedrion has in-licensed ProMetic’s technologies for the manufacturing of hyperimmune products in Europe. Royalties, licensing and service fees for the sales of products in
Visit of the Minister of reform and innovation in the Public Administration, Luigi Nicolais, to the Kedrion plant in Sant’Antimo (Naples)
The Minister of Reform and Innovation in the Public Administration, Luigi Nicolais, recently visited the Kedrion plant for the production of plasma-derived products in Sant’Antimo, near Naples. Kedrion Group, specialising in the production and distribution of pharmaceutical products derived from plasma proteins, has a total of three production plants: in addition to the one in
Paolo Marcucci has joined PPTA’s Global Board of Directors
Paolo Marcucci, President and CEO of Kedrion, has joined the Global Board of Directors of the Plasma Protein Therapeutics Association (PPTA). “We are excited that Mr. Marcucci is joining the Global Board of Directors” said Jan M. Bult, PPTA’s President. “Paolo Marcucci understands the many challenges confronting our industry and the patients we serve. He
European GMP, current issues and future developments: Kedrion in the organising committee of the EMA / PDA Joint Conference
Kedrion (Italy) is the only company working in the plasma derivatives industry which is sitting on the organising committee of the EMEA/PDA (Parenteral Drug Association) Joint Conference. The company appointed Claudia Nardini, in charge of Industrial Development and Research for the company and deputy president of the Italian chapter of the PDA, as its delegate;
Production of plasma-derived products to highest international quality standards: Kedrion technology for the new Moscow plant
Kedrion embarks on its second technology transfer to Russia following the one in Kirov, by signing an agreement in Moscow for the development of a plasma-derivatives production plant to the highest international quality, safety and efficiency standards. The agreement signed between Kedrion, the Dutch company BTI and the Moscow Government covers both the engineering operations